COMPASS Pathways plc (NASDAQ:CMPS) Receives $20.20 Consensus PT from Analysts

Shares of COMPASS Pathways plc (NASDAQ:CMPS) have earned a consensus recommendation of “Buy” from the six brokerages that are covering the firm, Marketbeat reports. Six research analysts have rated the stock with a buy recommendation. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $20.20.

Several brokerages recently issued reports on CMPS. Stifel Nicolaus initiated coverage on COMPASS Pathways in a report on Thursday, February 27th. They issued a “buy” rating and a $11.00 price target on the stock. Royal Bank of Canada reiterated an “outperform” rating and set a $18.00 price objective on shares of COMPASS Pathways in a research report on Wednesday, January 15th. Canaccord Genuity Group lowered their target price on COMPASS Pathways from $23.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, February 28th. HC Wainwright reiterated a “buy” rating and set a $45.00 price target on shares of COMPASS Pathways in a research report on Tuesday, March 4th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of COMPASS Pathways in a report on Friday, March 28th.

COMPASS Pathways Stock Down 4.3 %

CMPS stock opened at $3.82 on Thursday. The firm has a fifty day moving average price of $3.36 and a two-hundred day moving average price of $4.18. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.91 and a quick ratio of 8.91. COMPASS Pathways has a 1-year low of $2.49 and a 1-year high of $9.63. The firm has a market cap of $354.01 million, a price-to-earnings ratio of -1.74 and a beta of 2.34.

COMPASS Pathways (NASDAQ:CMPS) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.01). Research analysts predict that COMPASS Pathways will post -2.33 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. GAMMA Investing LLC lifted its position in shares of COMPASS Pathways by 93.6% in the 1st quarter. GAMMA Investing LLC now owns 10,349 shares of the company’s stock valued at $30,000 after acquiring an additional 5,003 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in shares of COMPASS Pathways in the fourth quarter valued at $41,000. Flagship Harbor Advisors LLC lifted its holdings in shares of COMPASS Pathways by 27.7% in the first quarter. Flagship Harbor Advisors LLC now owns 14,446 shares of the company’s stock valued at $41,000 after purchasing an additional 3,134 shares in the last quarter. Wealthfront Advisers LLC acquired a new stake in shares of COMPASS Pathways in the fourth quarter worth $43,000. Finally, OLD National Bancorp IN purchased a new position in shares of COMPASS Pathways during the first quarter valued at $45,000. 46.19% of the stock is currently owned by institutional investors and hedge funds.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.